The efficacy and safety of docetaxel chemotherapy in the treatment of localised high-risk prostate cancer: a Meta-analysis
10.3760/cma.j.issn.1000-6702.2019.11.012
- VernacularTitle: 多西他赛化疗对局限期高危前列腺癌疗效及安全性的荟萃分析
- Author:
Qingwei QIN
1
;
Na LI
1
;
Sheng WANG
1
;
Xue ZHAO
1
;
Zhaohui QIN
2
;
Yuanhu YAO
1
Author Information
1. Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
2. School of Public Health, Xuzhou Medical University, Xuzhou 221004, China
- Publication Type:Clinical Trail
- Keywords:
Prostatic neoplasms;
High-risk;
Docetaxel;
Prognosis;
Meta-analysis
- From:
Chinese Journal of Urology
2019;40(11):853-858
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The role of additional docetaxel chemotherapy in the treatment of localised high-risk prostate cancer (PCa) remains a controversy. This meta-analysis aimed to investigate the effect of additional docetaxel chemotherapy on localised high-risk PCa.
Methods:A computerized search was performed in Pubmed, Embase, Cochrane Library, Web of Science, CBM, CNKI, VIP and Wanfang Data to collect clinical controlled trails on localised high-risk PCa treated with docetaxel chemotherapy from the inception to April 2019. The Review Manager 5.3 software was used to perform meta-analysis of survival data and adverse events.
Results:Six literatures were enrolled, including 3 187 patients. Compared with the standard treatment (local treatment combined with endocrine therapy) group, the progression-free survival (PFS) was prolonged in the standard treatment plus docetaxel group, and the difference was statistically significant. [hazard ratio(HR)=0.75, 95%CI 0.65-0.86, P<0.01]. Patients in the standard treatment plus docetaxel group had longer overall survival (OS) and biochemical recurrence-free survival (BRFS) in comparison with standard treatment group, but the difference was not statistically significant (HR=0.843, 95%CI 0.68-1.01, P=0.06; HR=0.86, 95%CI 0.69-1.07, P=0.17). In terms of safety, the incidence of adverse reactions was increased in the standard treatment plus docetaxel group, including the incidence of grade ≥3 neutropenia (RR=44.14, 95%CI 19.15-101.71, P<0.01), the incidence of grade ≥3 febrile neutropenia (RR=13.4, 95%CI 7.93-22.65, P<0.01) and the incidence of grade ≥3 diarrhea (RR=13.43, 95%CI 3.21-56.16, P<0.01).
Conclusions:Additional docetaxel chemotherapy could significantly improve the PFS in localised high-risk PCa patients. OS and BRFS were prolonged, but the difference was not statistically significant.
